Status:
COMPLETED
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Anaphylaxis
Hypotension
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Background: * Omalizumab is an approved drug for the treatment of asthma by the Food and Drug Administration. * Researchers are now studying this drug in a double-blind placebo-controlled manner to a...
Detailed Description
Anaphylaxis is a severe systemic reaction caused by release of mediators from mast cells and basophils. Manifestations include cutaneous, respiratory, cardiovascular, or gastrointestinal signs and sym...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Volunteers must satisfy all of the following inclusion criteria to be eligible for this study.
- Subject must be at least 18 years of age and no older than 70 years of age.
- Diagnosis of idiopathic anaphylaxis, a diagnosis of exclusion, assigned after other causes of anaphylaxis and other diseases in the differential diagnoses have been considered.
- Anaphylaxis episodes (mild-severe) at least 6 times within the past 1 year period, documented according to medical records physician report, or patient report and 1 episode within the last 4 months, and with at least 1 of the following:
- Elevated serum tryptase above baseline within 2 hours of the event.
- Emergency room visit with documented anaphylaxis without an etiology established by the acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips-tongue-uvula) \[Grade 1\]\* and at least 1 of the following:
- Respiratory compromise or gastrointestinal involvement (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia, nausea, vomiting, or abdominal pain \[Grade 2\]\*).
- Reduced blood pressure or associated symptoms of end-organ dysfunction (e.g., hypotonia \[collapse\], syncope, or incontinence \[Grade 3\]\*).
- Hospitalization for anaphylaxis: hospital records with documented anaphylaxis without known cause established by the acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips-tongue-uvula) \[Grade 1\]\*) and at least one of the following:
- Respiratory compromise or gastrointestinal involvement (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia, nausea, vomiting, or abdominal pain \[Grade 2\]\*).
- Reduced blood pressure or associated symptoms of end-organ dysfunction (e.g., hypotonia \[collapse\], syncope, or incontinence \[Grade 3\]\*).
- Letter of referral, with copies of pertinent medical history and laboratory tests, from prospective study participant s local physician.
- Ability to give informed consent.
- Women of childbearing potential must have a negative beta-HCG serum or urine pregnancy test prior to each injection, and must agree to practice abstinence or effective contraception from initiation of the protocol and for 3 months following the last infusion of the study agent (effective contraception methods include abstinence; surgical sterilization of either partner, barrier methods such as diaphragm, condom, cap, or sponge; or hormonal contraception).
- Severity grading of anaphylaxis
- EXCLUSION CRITERIA:
- A volunteer who satisfies any of the following exclusion criteria will be ineligible to participate in this study.
- Presence of conditions which, in the judgment of the investigator or the referring physician, may put the subject at undue risk for study participation or travel (such as an acute infection, severe thrombocytopenia, coronary artery disease, uncontrolled hypertension, congestive heart failure, chronic beta blocker therapy such as atenolol or metoprolol, or myeloproliferative disease).
- History of malignancy
- Known cause for anaphylaxis or flushing
- Diagnosis of mastocytosis
- Inability to provide informed consent
- Inability or refusal to undergo a bone marrow biopsy and aspirate
- HIV positive or other known immunodeficiency
- Active or chronic hepatitis
- Use of any other investigational agent within 30 days of the study
- Current use of chronic-oral corticosteroids or other immunosuppressant medications
- Pregnant or nursing women
- Positive pregnancy test
- IgE levels and subject s weight that cause dosing to be above dosing guidelines.
Exclusion
Key Trial Info
Start Date :
April 27 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2019
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00890162
Start Date
April 27 2009
End Date
May 31 2019
Last Update
July 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892